These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29611512)

  • 1. New interventions offer prostate cancer hope.
    The Lancet Oncology
    Lancet Oncol; 2018 Apr; 19(4):427. PubMed ID: 29611512
    [No Abstract]   [Full Text] [Related]  

  • 2. Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    Inoue T; Sasaki T; Kato M; Masui S; Nishikawa K
    BJU Int; 2021 Nov; 128(5):550. PubMed ID: 34333840
    [No Abstract]   [Full Text] [Related]  

  • 3. Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer?
    Reis LO
    Eur Urol; 2018 Nov; 74(5):682-683. PubMed ID: 30170874
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
    Nakata W; Yamamichi G; Tsujimura G; Tsujimoto Y; Nin M; Tsujihata M
    Int J Urol; 2020 Jan; 27(1):87-89. PubMed ID: 31602723
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.
    Condon B; Liskaser G; Thangasamy IA; Murphy DG
    Curr Opin Urol; 2020 Jul; 30(4):620-622. PubMed ID: 31725005
    [No Abstract]   [Full Text] [Related]  

  • 6. Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?
    Higano C
    Nat Rev Urol; 2019 Jun; 16(6):335-336. PubMed ID: 31040439
    [No Abstract]   [Full Text] [Related]  

  • 7. Future of screening for prostate cancer.
    Dahm P
    BMJ; 2017 Sep; 358():j4200. PubMed ID: 28928226
    [No Abstract]   [Full Text] [Related]  

  • 8. AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?
    Tsaur I; Borgmann H; Surcel CI; Ost P; Ploussard G
    World J Urol; 2018 Jan; 36(1):149-151. PubMed ID: 29086020
    [No Abstract]   [Full Text] [Related]  

  • 9. New prostate cancer drugs hold promise.
    Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting the androgen receptor.
    Friedlander TW; Ryan CJ
    Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New hope in the treatment of advanced cancer of the prostate in 2012].
    Massard C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S3. PubMed ID: 23767051
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug development. New way to target hormone receptor thwarts prostate cancer.
    Kaiser J
    Science; 2009 Apr; 324(5924):165. PubMed ID: 19359556
    [No Abstract]   [Full Text] [Related]  

  • 13. Triple-acting drug boosts prostate cancer survival.
    Cancer Discov; 2011 Dec; 1(7):OF1. PubMed ID: 22586690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?
    Di Nunno V; Santoni M; Massari F
    Eur Urol Oncol; 2019 Jul; 2(4):471. PubMed ID: 31277785
    [No Abstract]   [Full Text] [Related]  

  • 15. The evolution of antiandrogens: MDV3100 comes of age.
    Dumas L; Payne H; Chowdhury S
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):131-3. PubMed ID: 22316360
    [No Abstract]   [Full Text] [Related]  

  • 16. Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
    Antonarakis ES
    Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
    Tombal B; Borre M; Rathenborg P; Werbrouck P; Van Poppel H; Heidenreich A; Iversen P; Braeckman J; Heracek J; Baskin-Bey E; Ouatas T; Perabo F; Phung D; Hirmand M; Smith MR
    Lancet Oncol; 2014 May; 15(6):592-600. PubMed ID: 24739897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer: What is the optimal treatment sequence for mCRPC?
    Sartor O
    Nat Rev Urol; 2016 Oct; 13(11):639-640. PubMed ID: 27797362
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-androgen monotherapy for metastatic prostate cancer.
    Attard G
    Lancet Oncol; 2014 May; 15(6):543-4. PubMed ID: 24739898
    [No Abstract]   [Full Text] [Related]  

  • 20. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
    Boegemann M
    Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.